Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciprofloxacin + fluocinolone acetonide (Beimei Pharmaceutical)
- Development stage
- Preclinical
- Lead developer
- Shenzhen Beimei Pharmaceutical
- Modality
- Small Molecules
- Administration
- Otic
01
Overview
BM-L12 is an investigational combination otic drug candidate being developed by Beimei Pharmaceutical (also known as Bainei Pharmaceutical) for the treatment of Acute Otitis Externa (AOE) and Acute Otitis Media (AOM). Licensed from Laboratorios SALVAT, the formulation consists of ciprofloxacin, a fluoroquinolone antibiotic, and fluocinolone acetonide, a potent corticosteroid. Ciprofloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and DNA topoisomerase 4, which are essential for bacterial DNA replication, transcription, and repair. Fluocinolone acetonide acts as a glucocorticoid receptor agonist, providing anti-inflammatory and antipruritic effects to reduce swelling and pain associated with ear infections. BM-L12 is currently in the IND-enabling phase in China, with plans for clinical development to support its use in pediatric and adult populations.
- Other names
- ciprofloxacin and fluocinolone acetonide otic solution
02
Targets
GR (Glucocorticoid receptor)Topo IV (Bacterial Topoisomerase IV)DNA gyrase
Beyond the preview
Go deeper on ciprofloxacin + fluocinolone acetonide (Beimei Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciprofloxacin + fluocinolone acetonide (Beimei Pharmaceutical).